Federal Register / Vol. 71, No. 211 / Wednesday, November 1, 2006 / Notices 64297 

market for the Subject Merchandise in 

each Subject Country since the Order 

Dates, and significant changes, if any, 

that are likely to occur within a 

reasonably foreseeable time. Supply 

conditions to consider include 

technology; production methods; 

development efforts; ability to increase 

production (including the shift of 

production facilities used for other 

products and the use, cost, or 

availability of major inputs into 

production); and factors related to the 

ability to shift supply among different 

national markets (including barriers to 

importation in foreign markets or 

changes in market demand abroad). 

Demand conditions to consider include 

end uses and applications; the existence 

and availability of substitute products; 

and the level of competition among the 

Domestic Like Product produced in the 

United States, Subject Merchandise 

produced in each Subject Country, and 

such merchandise from other countries. 

(11) (OPTIONAL) A statement of 

whether you agree with the above 

definitions of the Domestic Like Product 

and Domestic Industry; if you disagree 

with either or both of these definitions, 

please explain why and provide 

alternative definitions. 

Authority: These reviews are being 

conducted under authority of title VII of the 

Tariff Act of 1930; this notice is published 

pursuant to section 207.61 of the 

Commission’s rules. 

By order of the Commission. 

Issued: October 25, 2006. 

Marilyn R. Abbott, 

Secretary to the Commission. 

[FR Doc. E6–18311 Filed 10–31–06; 8:45 am] 

BILLING CODE 7020–02–P 

JOINT BOARD FOR THE 

ENROLLMENT OF ACTUARIES 

Advisory Committee on Actuarial 

Examinations; Invitation for 

Membership on Advisory Committee 

AGENCY: Joint Board for the Enrollment 

of Actuaries. 

ACTION: Withdrawal of notice inviting 

membership on advisory committee; 

notice inviting membership on advisory 

committee. 

SUMMARY: The Joint Board for the 

Enrollment of Actuaries (Joint Board), 

established under the Employee 

Retirement Income Security Act of 1974 

(ERISA), is responsible for the 

enrollment of individuals who wish to 

perform actuarial services under ERISA. 

The Joint Board has established an 

Advisory Committee on Actuarial 

Examinations (Advisory Committee) to 

assist in its examination duties 

mandated by ERISA. The Joint Board 

published a Federal Register notice at 

71 FR 30649, May 30, 2006, inviting 

membership on the Advisory 

Committee. That notice did not reflect 

the Joint Board’s decision to extend the 

appointment term of current Advisory 

Committee members. Therefore, this 

document withdraws the previous 

notice and gives new notice inviting 

membership. In accordance with the 

Joint Board’s decision, the appointment 

term of current Advisory Committee 

members will expire on February 28, 

2007. This notice describes the 

Advisory Committee and invites 

applications from those interested in 

serving on it. 

1. General 

To qualify for enrollment to perform 

actuarial services under ERISA, an 

applicant must have requisite pension 

actuarial experience and satisfy 

knowledge requirements as provided in 

the Joint Board’s regulations. The 

knowledge requirements may be 

satisfied by successful completion of 

Joint Board examinations in basic 

actuarial mathematics and methodology 

and in actuarial mathematics and 

methodology relating to pension plans 

qualifying under ERISA. 

The Joint Board, the Society of 

Actuaries, and the American Society of 

Pension Professionals & Actuaries 

jointly offer examinations acceptable to 

the Joint Board for enrollment purposes 

and acceptable to those actuarial 

organizations as part of their respective 

examination programs. 

2. Programs 

The Advisory Committee plays an 

integral role in the examination program 

by assisting the Joint Board in offering 

examinations that will enable 

examination candidates to demonstrate 

the knowledge necessary to qualify for 

enrollment. The purpose of the 

Advisory Committee, as renewed, will 

remain that of assisting the Joint Board 

in fulfilling this responsibility. The 

Advisory Committee will discuss the 

philosophy of such examinations, will 

review topics appropriately covered in 

them, and will make recommendations 

relative thereto. It also will recommend 

to the Joint Board proposed examination 

questions. The Joint Board will maintain 

liaison with the Advisory Committee in 

this process to ensure that its views on 

examination content are understood. 

3. Function 

The manner in which the Advisory 

Committee functions in preparing 

examination questions is intertwined 

with the jointly administered 

examination program. Under that 

program, the participating actuarial 

organizations draft questions and 

submit them to the Advisory Committee 

for its consideration. After review of the 

draft questions, the Advisory Committee 

selects appropriate questions, modifies 

them as it deems desirable, and then 

prepares one or more drafts of actuarial 

examinations to be recommended to the 

Joint Board. (In addition to revisions of 

the draft questions, it may be necessary 

for the Advisory Committee to originate 

questions and include them in what is 

recommended.) 

4. Membership 

The Joint Board will take steps to 

ensure maximum practicable 

representation on the Advisory 

Committee of points of view regarding 

the Joint Board’s actuarial examination 

extant in the community at large and 

from nominees provided by the 

actuarial organizations. Since the 

members of the actuarial organizations 

comprise a large segment of the 

actuarial profession, this appointive 

process ensures expression of a broad 

spectrum of viewpoints. All members of 

the Advisory Committee will be 

expected to act in the public interest, 

that is, to produce examinations that 

will help ensure a level of competence 

among those who will be accorded 

enrollment to perform actuarial services 

under ERISA. 

Membership normally will be limited 

to actuaries previously enrolled by the 

Joint Board. However, individuals 

having academic or other special 

qualifications of particular value for the 

Advisory Committee’s work also will be 

considered for membership. 

Membership terms are at the sole 

discretion of the inviting authority and 

are not necessarily concurrent with the 

duration of the Advisory Committee 

charter. The Advisory Committee will 

meet about four times a year. Advisory 

Committee members should be prepared 

to devote from 125 to 175 hours, 

including meeting time, to the work of 

the Advisory Committee over the course 

of a year. Members will be reimbursed 

for travel expenses incurred, in 

accordance with applicable government 

regulations. 

Actuaries interested in serving on the 

Advisory Committee should express 

their interest and fully state their 

qualifications in a letter addressed to: 

Joint Board for the Enrollment of 

Actuaries, c/o Internal Revenue Service, 

Attn: Executive Director SE: OPR, Room 

7238, 1111 Constitution Avenue, NW., 

Washington, DC 20224. 


sroberts on PROD1PC70 with NOTICES
64298 Federal Register / Vol. 71, No. 211 / Wednesday, November 1, 2006 / Notices 

Any questions may be directed to the 

Joint Board’s Executive Director at 202–

622–8229. 

The deadline for accepting 

applications is December 15, 2006. 

Dated: October 11, 2006. 

Patrick W. McDonough, 

Executive Director, Joint Board for the 

Enrollment of Actuaries. 

[FR Doc. 06–8992 Filed 10–31–06; 8:45 am] 

BILLING CODE 4830–01–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Prior to issuing a registration under 21 

U.S.C. 952(a)(2)(B), and in accordance 

with 21 CFR 1301.34(a), this is notice 

that on July 25, 2006, Alcan PackagingBethlehem, 2400 Baglyos Circle, 

Bethlehem, Pennsylvania, 18020, has 

made application to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of Nabilone 

(7379), a basic class of controlled 

substance listed in schedule II. 

The company plans to import the 

listed controlled substance for 

packaging and for distribution. 

Any manufacturer who is presently, 

or is applying to be, registered with DEA 

to manufacture such basic class of 

controlled substance may file comments 

or objections to the issuance of the 

proposed registration and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such written comments or 

objections being sent via regular mail 

should be addressed, in quintuplicate, 

to the Deputy Assistant Administrator, 

Office of Diversion Control, Drug 

Enforcement Administration, 

Washington, DC 20537, Attention: DEA 

Federal Register Representative/ODL; or 

any being sent via express mail should 

be sent to DEA Headquarters, Attention: 

DEA Federal Register Representative/ 

ODL, 2401 Jefferson-Davis Highway, 

Alexandria, Virginia 22301; and must be 

filed no later than December 1, 2006. 

This procedure is to be conducted 

simultaneously with and independent 

of the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance listed in 

schedule I or II are, and will continue 

to be, required to demonstrate to the 

Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a), 21 U.S.C. 823(a), and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: October 25, 2006. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E6–18431 Filed 10–31–06; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By notice dated July 25, 2006, and 

published in the Federal Register on 

July 31, 2006, (71 FR 43210), Aptuit, 

10245 Hickman Mills Drive, Kansas 

City, Missouri 64137, made application 

by letter to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of Marihuana (7360), a basic 

class of controlled substance listed in 

schedule I. 

The company plans to import a 

finished pharmaceutical product 

containing cannabis extracts in dosage 

form for packaging for a clinical trial 

study. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Aptuit to import the basic class of 

controlled substance is consistent with 

the public interest and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971, at this time. DEA 

has investigated Aptuit to ensure that 

the company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed 

Dated: October 25, 2006. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E6–18376 Filed 10–31–06; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on August 28, 2006, 

Cambrex Charles City, Inc., 1205 11th 

Street, Charles City, Iowa 50616, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Sufentanil (9740), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to manufacture 

the listed controlled substance in bulk 

for distribution to its customers. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such a substance 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections being sent via regular mail 

should be addressed, in quintuplicate, 

to the Deputy Assistant Administrator, 

Office of Diversion Control, Drug 

Enforcement Administration, 

Washington, DC 20537, Attention: DEA 

Federal Register Representative/ODL; or 

any being sent via express mail should 

be sent to DEA Headquarters, Attention: 

DEA Federal Register Representative/ 

ODL, 2401 Jefferson-Davis Highway, 

Alexandria, Virginia 22301; and must be 

filed no later than January 2, 2007. 

Dated: October 25, 2006. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E6–18375 Filed 10–31–06; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By notice dated July 26, 2006, and 

published in the Federal Register on 

August 1, 2006, (71 FR 43526), Kenco 

VPI, Division of Kenco Group Inc., 350 


sroberts on PROD1PC70 with NOTICES